Ashermed
- Company typePrivate
- Founded2011
- HeadquartersShanghai, China
- Headcount1–10
- GTM typeB2B
- OfferingServices
Ashermed firmographics
Firmographics- Name
- Ashermed
- Legal name
- 上海艾莎医学科技有限公司
- Website
- https://ashermed.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Ashermed industry classification
Industry- Product category
- Clinical Research Organization (CRO) Services
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Engineering, Accounting, Research, Management (8700)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)
Keywords
Where Ashermed is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices4 records
Markets served
Ashermed business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- CRO Services: Contract Research Organization services providing comprehensive clinical research support including protocol design, site management, monitoring, and data management.
- SMO Services: Site Management Organization services for on-site clinical trial support and site coordination.
- Patient Recruitment Services: Patient screening, recruitment, aid, education, and follow-up services. Includes rare disease patient management platforms.
- Digital Platform Services: Digital clinical research platform software and technology services including SSU (Site Start-Up), DCT (Decentralized Clinical Trials), and integrated hospital system connections.
- Medical Value Communication: Evidence-based medical value communication services for pharmaceutical and medical device product lifecycle management, including CME, KOL interviews, case studies, and guideline training.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Ashermed product offering
Product offeringCore offering
Ashermed (艾莎医学) is an innovative digital clinical Contract Research Organization (CRO) providing comprehensive clinical research services for pharmaceutical and medical device companies in China. The company delivers CRO, SMO, patient recruitment, and digital platform support services through a self-developed digital product matrix (eProtocol, EDC, CTMS, ePRO) backed by AI-powered medical knowledge graph and multi-modal data processing capabilities.
Differentiator
Problem solved
Functional benefit
Products and services
- eProtocol Digital Protocol Design System (eProtocol方案设计系统)
- EDC Electronic Data Capture System (EDC电子数据采集系统)
- CTMS Clinical Trial Management System (CTMS临床试验项目管理系统)
- ePRO Electronic Patient-Reported Outcome System (ePRO患者电子报告系统)
- CRO Services (CRO服务)
- SMO Services (SMO服务)
- Patient Recruitment Services (患者招募服务)
- Digital Platform Support (数字化平台支持)
- Hepatology Academy (肝病学苑)
- iHemater Hematology Cloud Expert (iHemater血液病云专家)
- Jianyu Mutual Aid Home (渐愈互助之家)
- Medical Value Communication Services
Quantifiable outcome
- 70% reduction in project manual labor investment
- +5 more outcomes
Companies that use Ashermed
Customer profileNamed customers11 records
Segments4 records
Ideal customer profiles3 records
Ashermed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability7 records
Feature7 records
Ashermed partnerships and signals
Strategic signalPartnerships
19 partnerships are on record, tiered core, major and key client.
- Beijing Friendship Hospital (首都医科大学附属北京友谊医院)coreJoint development of clinical research digital management platform to improve research efficiency and quality through system integration.
- Shanxi Bethune Hospital Clinical Trial Institution (山西白求恩医院临床试验机构)coreStrategic cooperation for clinical research collaboration, leveraging hospital's clinical trial infrastructure and Ashermed's digital platform capabilities.
- Guangdong Province Zhong Nanshan Medical Foundation (广东省钟南山医学基金会)coreStrategic partnership to leverage digital AI capabilities for efficient scientific research and public welfare project management.
- JD Group (京东集团)coreJointly established rare disease patient management platform. Successfully gathered over 6,000 verified ALS patients within one year and completed patient recruitment for four ALS clinical trials.
- Peking Union Medical College Hospital (北京协和医院)majorLeading academic medical center partnership for clinical research collaboration.
- West China Hospital of Sichuan University (四川大学华西医院)majorTop-tier teaching hospital partnership for multi-center clinical research.
- Wuhan Union Hospital (武汉协和医院)majorMajor tertiary hospital partnership for clinical research collaboration.
- Shanghai Ruijin Hospital (上海瑞金医院)majorLeading Shanghai-based teaching hospital partnership for clinical research.
- Chinese Foundation for Hepatitis Prevention and Control (中国肝炎防治基金会)majorFoundation partnership for hepatitis prevention and control research projects.
- Bethune Charitable Foundation (白求恩公益基金会)majorCharitable foundation partnership for clinical research and public welfare projects.
- Wu Jieping Medical Foundation (吴阶平医学基金会)majorMedical foundation partnership supporting clinical research initiatives.
- China Medical and Health Development Foundation (中国医药卫生事业发展基金会)majorFoundation partnership for medical and health development projects.
- Pfizer (辉瑞)key clientGlobal pharmaceutical company served as a client for clinical research services.
- Roche (罗氏)key clientGlobal pharmaceutical company served as a client for clinical research services.
- Novartis (诺华)key clientGlobal pharmaceutical company served as a client for clinical research services.
- Takeda (武田制药)key clientJapanese pharmaceutical company served as a client for clinical research services.
- Eli Lilly (礼来)key clientGlobal pharmaceutical company served as a client for clinical research services.
- Hengrui Medicine (恒瑞医药)key clientLeading domestic pharmaceutical company served as a client for clinical research services.
- BeiGene (百济神州)key clientGlobal oncology-focused biotech company served as a client for clinical research services.
Scale indicators9 records
Ashermed competitors and assessment
Company assessmentDirect peers
- Tigermed (Hangzhou Tigermed Consulting): Hangzhou Tigermed is the largest China-headquartered clinical CRO offering full-service Phase I-IV clinical trial management, biostatistics, and site management. Direct competitor for the same multinational and domestic pharma clients in China, with broader scale and global footprint.
- Frontage Holdings: Frontage is a US-China clinical CRO providing bioanalytical, CMC, and clinical research services with a strong China footprint. Comparable in mid-tier clinical CRO positioning and overlap with Ashermed in pharma/biotech sponsors.
- Medpace: Medpace is a mid-size, science-focused global clinical CRO known for full-service trial execution across multiple therapeutic areas. Comparable in its lean, technology-enabled CRO operating model and overlap with Ashermed in mid-cap pharma sponsors.
Broad incumbents
- WuXi AppTec: WuXi AppTec is a global CRO/CDMO with extensive clinical research services in China and worldwide. It is a broader incumbent whose clinical CRO business competes directly with Ashermed for pharma sponsors, while also offering preclinical, manufacturing, and biologics services.
- Pharmaron: Pharmaron is a China-based, globally integrated CRO/CDMO offering laboratory, CMC, and clinical research services. It competes with Ashermed for China-based clinical trial work while operating a much broader service portfolio.
- ICON plc: ICON is one of the world's largest clinical CROs offering full-service Phase I-IV trial management, decentralized trials, and real-world evidence globally. It is a broader incumbent whose digital trial capabilities overlap with Ashermed's positioning.
- IQVIA: IQVIA is the largest global clinical CRO and life sciences data/technology provider. It competes with Ashermed for global pharma clinical work in China and offers overlapping decentralized trial, real-world evidence, and AI-enabled data services.
- Charles River Laboratories: Charles River is a global CRO/CDMO with clinical trial services spanning early-phase through post-marketing. It is a broader incumbent whose China clinical research operations compete with Ashermed, particularly for multinational sponsors.
- Parexel: Parexel is a global clinical CRO serving pharma and biotech sponsors across Phase I-IV and post-approval studies. It competes with Ashermed for multinational clinical work, including in China, with a broader service portfolio.
Regional players
- Novotech (Novotech Health Holdings): Novotech is an Asia-Pacific-focused clinical CRO with strong presence in China, Australia, and South Korea. It is a regional peer competing for similar biotech sponsors running trials in Asia, with comparable mid-tier CRO positioning to Ashermed.
Market position
Customer concentration
Ashermed compliance and trust
Trust signalCompliance4 records
Ashermed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ashermed leadership team
Management profileNumber of profiles
Ashermed funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ashermed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ashermed
What does Ashermed do?
Ashermed (艾莎医学) is an innovative digital clinical Contract Research Organization (CRO) providing comprehensive clinical research services for pharmaceutical and medical device companies in China. The company delivers CRO, SMO, patient recruitment, and digital platform support services through a self-developed digital product matrix (eProtocol, EDC, CTMS, ePRO) backed by AI-powered medical knowledge graph and multi-modal data processing capabilities.
Is Ashermed a public or private company?
Ashermed is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ashermed founded?
Ashermed was founded in 2011. It employs 1 to 10 people.
Where is Ashermed based?
Ashermed is headquartered in Shanghai, China, in the Asia region.
How does Ashermed make money?
Five revenue lines are on record. CRO Services are the primary driver. The others are SMO Services, patient Recruitment Services, digital Platform Services and medical Value Communication.
Who are Ashermed's main competitors?
Direct peers on record are Tigermed (Hangzhou Tigermed Consulting), Frontage Holdings and Medpace. Broad incumbents are WuXi AppTec, Pharmaron, ICON plc, IQVIA, Charles River Laboratories and Parexel. Novotech (Novotech Health Holdings) is listed as a regional player.
Does Ashermed have an API?
No public API is recorded for Ashermed.
What industry is Ashermed in?
Ashermed's product category is Clinical Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 54171 and its SIC code is 8700.